- Home
- PYPD vs MRSN Comparison
PYPD vs MRSN Comparison
Compare PYPD & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PYPD
- MRSN
- Stock Information
- Founded
- PYPD 2008
- MRSN 2001
- Country
- PYPD Israel
- MRSN United States
- Employees
- PYPD N/A
- MRSN N/A
- Industry
- PYPD Medical/Dental Instruments
- MRSN Biotechnology: Pharmaceutical Preparations
- Sector
- PYPD Health Care
- MRSN Health Care
- Exchange
- PYPD Nasdaq
- MRSN Nasdaq
- Market Cap
- PYPD 34.8M
- MRSN 37.0M
- IPO Year
- PYPD 2020
- MRSN 2017
- Fundamental
- Price
- PYPD $3.37
- MRSN $7.32
- Analyst Decision
- PYPD Strong Buy
- MRSN Strong Buy
- Analyst Count
- PYPD 5
- MRSN 4
- Target Price
- PYPD $12.00
- MRSN $63.67
- AVG Volume (30 Days)
- PYPD 71.2K
- MRSN 97.8K
- Earning Date
- PYPD 08-13-2025
- MRSN 08-13-2025
- Dividend Yield
- PYPD N/A
- MRSN N/A
- EPS Growth
- PYPD N/A
- MRSN N/A
- EPS
- PYPD N/A
- MRSN N/A
- Revenue
- PYPD N/A
- MRSN $34,769,000.00
- Revenue This Year
- PYPD N/A
- MRSN N/A
- Revenue Next Year
- PYPD N/A
- MRSN N/A
- P/E Ratio
- PYPD N/A
- MRSN N/A
- Revenue Growth
- PYPD N/A
- MRSN 16.14
- 52 Week Low
- PYPD $2.30
- MRSN $5.21
- 52 Week High
- PYPD $3.93
- MRSN $70.75
- Technical
- Relative Strength Index (RSI)
- PYPD 48.80
- MRSN 48.13
- Support Level
- PYPD $3.35
- MRSN $7.41
- Resistance Level
- PYPD $3.56
- MRSN $8.05
- Average True Range (ATR)
- PYPD 0.16
- MRSN 0.60
- MACD
- PYPD 0.00
- MRSN 0.10
- Stochastic Oscillator
- PYPD 65.56
- MRSN 70.73
About PYPD PolyPid Ltd.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.